Psychedelic Bulletin: MAPS Study Published in Nature Medicine; Numinus’ Hiring Spree; CB Therapeutics’ Series A Post published:May 14, 2021 Post category:Psychedelic Bulletin
Psychedelic Bulletin: MDMA Sees Success at Phase 3; MindMed Targets Pain; the Proliferation of Deuteration Post published:May 8, 2021 Post category:Psychedelic Bulletin
Psychedelic Bulletin: MindMed Uplists to Nasdaq; Cybin Targets Alcoholism; COMPASS Announces $144m Offering Post published:April 30, 2021 Post category:Psychedelic Bulletin
Psychedelic Bulletin: MindMed to List on Nasdaq; Atai IPO Unveiled; Champignon Brands Resumes Trading Post published:April 23, 2021 Post category:Psychedelic Bulletin
Psychedelic Bulletin: Experts Weigh in on Psilocybin vs. SSRIs; GH Research Closes $125m Round; California Decrim. Bill Passes 2nd Key Committee Post published:April 16, 2021 Post category:Psychedelic Bulletin
Psychedelic Bulletin: CA Decrim. Bill Passes Key Committee; MindMed Publishes MDMA Dosing Study; atai Acquires DTx Company Post published:April 9, 2021 Post category:Psychedelic Bulletin
Psychedelic Bulletin: UCSF Launches Psychedelics Division; New Additions to the Psychedelics ETF; Massachusetts City Decriminalizes Psychedelics Post published:April 2, 2021 Post category:Psychedelic Bulletin
Psychedelic Bulletin: UW-Madison Launches Psychedelic Master’s Program; COMPASS Granted 2 Patents Post published:March 26, 2021 Post category:Psychedelic Bulletin
Psychedelic Bulletin: Australian Gov Earmarks $15m for Psychedelic Studies; Otsuka Licences R-ketamine in Japan; DC Initiative Becomes Law Post published:March 19, 2021 Post category:Psychedelic Bulletin
Psychedelic Bulletin: Harvard Revisits Psychedelics; MindMed Attracts Strategic Investor; Psychedelics Companies Shed Cannabis Assets Post published:March 12, 2021 Post category:Psychedelic Bulletin